Cargando…
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profil...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850440/ https://www.ncbi.nlm.nih.gov/pubmed/35173208 http://dx.doi.org/10.1038/s41598-022-06498-9 |
_version_ | 1784652599092314112 |
---|---|
author | Jungwirth, Jiri Urbanova, Marketa Boot, Arnoud Hosek, Petr Bendova, Petra Siskova, Anna Svec, Jiri Kment, Milan Tumova, Daniela Summerova, Sandra Benes, Zdenek Buchler, Tomas Kohout, Pavel Hucl, Tomas Matej, Radoslav Vodickova, Ludmila van Wezel, Tom Vodicka, Pavel Vymetalkova, Veronika |
author_facet | Jungwirth, Jiri Urbanova, Marketa Boot, Arnoud Hosek, Petr Bendova, Petra Siskova, Anna Svec, Jiri Kment, Milan Tumova, Daniela Summerova, Sandra Benes, Zdenek Buchler, Tomas Kohout, Pavel Hucl, Tomas Matej, Radoslav Vodickova, Ludmila van Wezel, Tom Vodicka, Pavel Vymetalkova, Veronika |
author_sort | Jungwirth, Jiri |
collection | PubMed |
description | A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma—high-grade adenomas—in situ carcinoma: APC gene 42.9–56.0–54.5%; KRAS gene 32.7–32.0–45.5%; TP53 gene 8.2–20.0–18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS. |
format | Online Article Text |
id | pubmed-8850440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88504402022-02-17 Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition Jungwirth, Jiri Urbanova, Marketa Boot, Arnoud Hosek, Petr Bendova, Petra Siskova, Anna Svec, Jiri Kment, Milan Tumova, Daniela Summerova, Sandra Benes, Zdenek Buchler, Tomas Kohout, Pavel Hucl, Tomas Matej, Radoslav Vodickova, Ludmila van Wezel, Tom Vodicka, Pavel Vymetalkova, Veronika Sci Rep Article A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma—high-grade adenomas—in situ carcinoma: APC gene 42.9–56.0–54.5%; KRAS gene 32.7–32.0–45.5%; TP53 gene 8.2–20.0–18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS. Nature Publishing Group UK 2022-02-16 /pmc/articles/PMC8850440/ /pubmed/35173208 http://dx.doi.org/10.1038/s41598-022-06498-9 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jungwirth, Jiri Urbanova, Marketa Boot, Arnoud Hosek, Petr Bendova, Petra Siskova, Anna Svec, Jiri Kment, Milan Tumova, Daniela Summerova, Sandra Benes, Zdenek Buchler, Tomas Kohout, Pavel Hucl, Tomas Matej, Radoslav Vodickova, Ludmila van Wezel, Tom Vodicka, Pavel Vymetalkova, Veronika Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title | Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title_full | Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title_fullStr | Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title_full_unstemmed | Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title_short | Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
title_sort | mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850440/ https://www.ncbi.nlm.nih.gov/pubmed/35173208 http://dx.doi.org/10.1038/s41598-022-06498-9 |
work_keys_str_mv | AT jungwirthjiri mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT urbanovamarketa mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT bootarnoud mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT hosekpetr mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT bendovapetra mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT siskovaanna mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT svecjiri mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT kmentmilan mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT tumovadaniela mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT summerovasandra mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT beneszdenek mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT buchlertomas mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT kohoutpavel mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT hucltomas mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT matejradoslav mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT vodickovaludmila mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT vanwezeltom mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT vodickapavel mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition AT vymetalkovaveronika mutationalanalysisofdrivergenesdefinesthecolorectaladenomainsitucarcinomatransition |